Combretastatin A4

For research use only. Not for use in humans.

Catalog No.S7783

2 publications

Combretastatin A4 Chemical Structure

Molecular Weight(MW): 316.35

Combretastatin A4 is a microtubule-targeting agent that binds β-tubulin with Kd of 0.4 μM.Phase 3.

Size Price Stock Quantity  
USD 97 In stock
USD 397 In stock
USD 997 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Purity & Quality Control

Choose Selective Microtubule Associated Inhibitors

Biological Activity

Description Combretastatin A4 is a microtubule-targeting agent that binds β-tubulin with Kd of 0.4 μM.Phase 3.
Targets
β-tubulin [1]
0.4 μM(Kd)
In vitro

Combretastatin A4 inhibits the growth of MDA-MB-231, A549, Hela, HL-60, SF295, HCT-8, MDA-MB435, PC3M, OVCAR-8, NCI-H358M, and lymphocyte cells with IC50 of 2.8, 3.8, 0.9, 2.1, 6.2, 5.3, 7.9, 4.7, 0.37, 8, and 3.2 nM, respectively.[1] [2] 1 μM Combretastatin A4 inhibits tubulin polymerization by 35%, and 10 μM nearly completely blocks tubulin polymerization. Combretastatin A4 demonstrates great relative binding capacity, reaching 78% of colchicine binding.[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SKMEL-5 MknoS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NG\XO5hEgXSxdH;4bYMh[2:wY3XueJJifGmxbjDy[ZF2cXKnZDD0c{BqdmirYnn0JFUxLSClZXzsJIdzd3e2aDDpckBUU02HTD21JI1mdGGwb33hJINmdGxibHnu[ZMtKEWGNUC9N{4xOEVvMEig{txO NGq1eXMyQDd3M{Ww
A-549 NWjVfJR3T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NHz5NVdEgXSxdH;4bYMh[2:wY3XueJJifGmxbjDy[ZF2cXKnZDD0c{BqdmirYnn0JFUxLSClZXzsJIdzd3e2aDDpckBCNTV2OTDseY5oKGOjcnPpco9u[SClZXzsJIxqdmW|LDDFSFUxRTFwMkDFMVA3KM7:TR?= MYexPFc2OzVy
MCF-7 M{L0Nmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Mnn3R5l1d3SxeHnjJINwdmOnboTyZZRqd25icnXxeYlz\WRidH:gbY5pcWKrdDC1NEUh[2WubDDndo94fGhiaX6gUWNHNTdiYoLlZZN1KGOjcnPpco9u[SClZXzsJIxqdmW|LDDFSFUxRTNwOEDFMVA3KM7:TR?= MorWNVg4PTN3MB?=
HT-29 NF\Z[FJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NIC4cHBEgXSxdH;4bYMh[2:wY3XueJJifGmxbjDy[ZF2cXKnZDD0c{BqdmirYnn0JFUxLSClZXzsJIdzd3e2aDDpckBJXC1{OTDjc4xwdiCjZHXuc4NiemOrbn;tZUBk\WyuIHzpcoV{NCCHREWwQVEvOjCHLUC2JO69VQ>? NX70fG5zOTh5NUO1NC=>
MLM melanoma cell NGL2e4FIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MY\DfZRwfG:6aXOgZ49v[2WwdILheIlwdiC{ZYH1bZJm\CC2bzDpcohq[mm2IEWwKUBk\WyuIHfyc5d1cCCrbjDNUG0hdWWuYX7vcYEh[2WubDDsbY5meyxiRVS1NF0yNjRyRT2wOkDPxE1? MnP5NVg4PTN3MB?=
M14 M{e5OmN6fG:2b4jpZ4l1gSCjc4PhfS=> NVyyXINFUW5idnn0do8h[3m2b4TvfIlkKGGldHn2bZR6KHejczD0[ZN1\WRiYXfhbY5{fCCqdX3hckBu\Wyjbn;tZUBk[W6lZYKgLG0yPCliY3XscEBtcW6nLDDHTVUxRTBwMECwNUDPxE1? MnPpNVI4Ojl4NEC=
SK-OV3 MVHDfZRwfG:6aXPpeJkh[XO|YYm= NELiUHJKdiC4aYTyc{BkgXSxdH;4bYMh[WO2aY\peJkhfGW|dHXkJIFo[Wmwc4SgbJVu[W5ib4\hdolidiClYX7j[ZIhMFONLV;WN{kh[2WubDDsbY5mNCCJSUWwQVAvODByMTFOwG0> M1TDclEzPzJ7NkSw
HL60 cells M1G1T2N6fG:2b4jpZ4l1gSCjc4PhfS=> MYG3NkBp NFLCe5ZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJVDZyIHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9NE4xODBzIN88US=> NGTMVJgzODd|MUO1OS=>
SK-OV-3 MnzXS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NGDBbYI1QCCq NV[1NGxWT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hW0tvT2[tN{Bi\nSncjC0PEBpenNiYomgV3JDKGG|c3H5MEBIUTVyPUCuNFAxOTNizszN NVLSR2hWOTh5MkKxNlc>
HepG2 cells NVTSSWVbS3m2b4TvfIlkcXS7IHHzd4F6 MWjDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDI[ZBIOiClZXzsd{whUUN3ME2wMlAxODF2IN88US=> NIeyTW8yPzF{N{C2NS=>
ZR-75-1 M1myOGN6fG:2b4jpZ4l1gSCjc4PhfS=> MlzCR5l1d3SxeHnjbZR6KGGpYXnud5QhYlJvN{WtNUBk\WyuIHzpcoUtKEmFNUC9NE4xODB{NDFOwG0> M{S0VVE4OjR7NkS5
HeLa cell NWG3fVV5S3m2b4TvfIlkcXS7IHHzd4F6 NE\T[GJEgXSxdH;4bYNqfHliYXfhbY5{fCCKZVzhJINmdGxibHnu[UwhUUN3ME2wMlAxODNizszN MlfGNVczPDl4NEm=
HCT116 cell NFL5Z3FEgXSxdH;4bYNqfHliYYPzZZk> M1uzPWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KEiFVEGxOkBk\WyuIHzpcoUtKEmFNUC9NE4xODB|NTFOwG0> MXKxO|I1QTZ2OR?=
KBV1 cells M2jrTGN6fG:2b4jpZ4l1gSCjc4PhfS=> MmHwO|IhcA>? MWfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjD2bY5jdGG|dHnu[U1z\XOrc4ThcpQhU0KYMTDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVAvODByNDFOwG0> MmPRNlA4OzF|NUW=
SKOV3 M2rGR2N6fG:2b4jpZ4l1gSCjc4PhfS=> MXnDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTT29XOyClZXzsd{BjgSCVUlKgZZN{[XluIFfJOVA:OC5yMEC0NkDPxE1? NXrHZWJxOjRyMU[wNFI>
SKOV3 cells M4fmXmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NUXKfoJCT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hW0uRVkOgZ4VtdHNiYomgd5Vt\m:{aH;kZY1qdmViQjDhd5NigSxiR1m1NF0xNjByMESyJO69VQ>? MoTFNlM4PzJ|MEm=
HeLa cells Ml\uR5l1d3SxeHnjbZR6KGG|c3H5 M3nFWmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhmVGFiY3XscJMh[nliTWTUJIF{e2G7LDDJR|UxRTBwMECwOVEh|ryP Mlr3NVk5Pzl5NUi=
DU145 cells NXLtephTS3m2b4TvfIlkcXS7IHHzd4F6 MXfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDEWVE1PSClZXzsd{BjgSCVUlKgZZN{[XluIFfJOVA:OC5yMEC1OEDPxE1? MUKyOFAyPjByMh?=
DU145 cells NEGxU5VIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MVjHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDEWVE1PSClZXzsd{BjgSC|dXzmc5Jpd2SjbXnu[UBDKGG|c3H5MEBIUTVyPUCuNFAxPTRizszN M4\vV|I{Pzd{M{C5
SK-N-BE NYG3R2FrWHKxbHnm[ZJifGmxbjDhd5NigQ>? Moe3O|IhcA>? MWPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDpckBpfW2jbjDTT{1PNUKHIHPlcIx{KGG|c3Xzd4VlKGG|IHPlcIwhfmmjYnnsbZR6KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9NE4xODB3ODFOwG0> NIT2ZnczOjN{OUW2NS=>
NCIH460 cells NYrDUVBVS3m2b4TvfIlkcXS7IHHzd4F6 NWTIU|A4PDhiaB?= Mn\JR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUmNKUDR4MDDj[YxteyCjZoTldkA1QCCqcoOgZpkhW1KEIHHzd4F6NCCJSUWwQVAvODByNjFOwG0> Mkj3NVg{ODN6NEm=
KB-VIN10 cells NGW5fpdRem:uaX\ldoF1cW:wIHHzd4F6 MoKyO|IhcA>? NHGwU41CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFvCMXZKVjFyIHPlcIx{KG:4ZYKt[ZhxemW|c3nu[{BRNWeyIEG3NE9OTFJzIHHmeIVzKDd{IHjyd{BjgSCvZYTofYxmdmViYnz1[UBie3OjeTygTWM2OD1yLkCwNFch|ryP NHLufJIzOTZ2MUewNC=>
HCT116 cells NXu3bY02S3m2b4TvfIlkcXS7IHHzd4F6 M2W3R|czKGh? MWPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh[XO|ZYPz[YQh[XNicnXkeYN1cW:wIH;mJHs{UF22aIntbYRqdmViaX7jc5Jxd3KjdHnvckBi\nSncjC3NkBpenNiYomgd4NqdnSrbHzheIlwdiClb4XueIlv\yxiSVO1NF0xNjByMEe0JO69VQ>? M2XNRlIyQTV3NEW0
DU145 cells M1;Tc2N6fG:2b4jpZ4l1gSCjc4PhfS=> M2C5flQ5KGh? NH3N[o5EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBFXTF2NTDj[YxteyCjZoTldkA1QCCqcoOgZpkhW1KEIHHzd4F6NCCJSUWwQVAvODByODFOwG0> NFP6cJoyQDNyM{i0PS=>
RS4:11 cells MmXEVJJwdGmoZYLheIlwdiCjc4PhfS=> Ml;HO|IhcA>? MW\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFKVNEqxNUBk\WyuczDh[pRmeiB5MjDodpMh[nliKEOtLFQtPS2maX3leIh6dHSqaXH6c4wuOi27bDmtNkw2NWSrcHjlcpltfGW2cnH6c4xqfW1iYoLvcYll\SC2ZYP0MEBKSzVyPUCuNFAxQCEQvF2= M2HnWVI2Pzh3NkC1
HCT 116 NXnZb3NtT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NGKxTXNEd26lZX70doF1cW:wIIfobYNpKHC{b3T1Z4V{KDVyJTDpcohq[mm2aX;uJI9nKGe{b4f0bEBw\iCqdX3hckBkd2yxbjD0eY1weiCKQ2SgNVE3NCCLQ{WwQVAvODByOTFOwG0> MlT0NVE4OTR4MUO=
HeLa cells MmDCR5l1d3SxeHnjbZR6KGG|c3H5 NFPIXIE4OiCq MVzDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDI[WxiKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDy[ZNignW{aX6gZoF{\WRiZnz1c5Jme2OnbnPlJIF{e2G7LDDJR|UxRTBwMECwPUDPxE1? MnHRNlQ3Pjl6OEi=
BNL 1ME A.7R.1 cells M3H3eGN6fG:2b4jpZ4l1gSCjc4PhfS=> MnL4R5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRm5NKDGPRTDBMldTNjFiY3XscJMtKEmFNUC9NE4xODB7IN88US=> M{PTWVI2Pzh3NkC1
Calu6 NFPwZ3lRem:uaX\ldoF1cW:wIHHzd4F6 NXflS5lmPDhiaB?= Mn;GRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCFYXz1OkBi\nSncjC0PEBpenNiYomgd5Bm[3S{b4Doc5RwdWW2comsJGlEPTB;MD6wNFA6PCEQvF2= NUTyN4ozOjF5N{S0PVk>
melanoma B16 cell NF;rV5BIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NFmyNVhEd26lZX70doF1cW:wIIfobYNpKHC{b3T1Z4V{KDVyJTDpcohq[mm2aX;uJI9nKGe{b4f0bEBw\iCvdYLpcoUhdWWuYX7vcYEhSjF4IHPlcIwhdGmwZTygTWM2OD1yLkCwNUDPxE1? NV7WVHRjOTF5MUS2NVM>
DU145 cells NWj4U|BzS3m2b4TvfIlkcXS7IHHzd4F6 MXTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDEWVE1PSClZXzsd{BjgSCVUlKgZZN{[XluIFfJOVA:OC5yMEGg{txO M3;ES|IxPDl4OUKz
HCT116 cells Mlz3VJJwdGmoZYLheIlwdiCjc4PhfS=> MkO4O|IhcA>? M4HZXWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFPUNVE3KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHMh[XO|YYmsJGlEPTB;MD6wNFEh|ryP Mo\CNlEyOTJzM{C=
HCT15 cells MXLQdo9tcW[ncnH0bY9vKGG|c3H5 NGPp[G04OiCq M2TXS2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFPUNVUh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UV{Bie3OjeTygTWM2OD1yLkCwNUDPxE1? MX[yNVEyOjF|MB?=
HL60 cells Ml\lVJJwdGmoZYLheIlwdiCjc4PhfS=> NFjPZVU4OiCq MlXQRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKTE[wJINmdGy|IHHzd4V{e2WmIHHzJIdzd3e2aDDpcohq[mm2aX;uJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MD6wNFEh|ryP MkDTNlE3PjN|MUm=
A10 cells M3;5Zmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M{X2UFQ5KGh? NHXafFFIem:5dHigbY5pcWKrdHnvckBw\iC{YYSgRVExKGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MD6wNFEh|ryP MnLINlIxPDRzNkS=
HUVEC cells M1XQeGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M{jPclQ5KGh? M3K0d2dzd3e2aDDpcohq[mm2aX;uJI9nKEiXVlXDJINmdGy|IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:OC5yMEGg{txO M3TBXFIzODR2MU[0
HL60 cells M2D0fGN6fG:2b4jpZ4l1gSCjc4PhfS=> NFnNbVI4OiCq MXHDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIUFYxKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MD6wNFEh|ryP M1u4fFIzOTN4M{Gy
HL60 cells MnX0VJJwdGmoZYLheIlwdiCjc4PhfS=> MmLFO|IhcA>? MYLBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiONkCgZ4VtdHNiYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1yLkCwNUDPxE1? M2rOXFIzPTd6MUGx
NCI-H522 cells NF32XmdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MnrFOFghcA>? NIrPR|hIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEWyNkBk\WyuczDh[pRmeiB2ODDodpMh[nliU2LCJIF{e2G7LDDHTVUxRTBwMECxJO69VQ>? Mn\NNlI6QDJzMkK=
MDA-MB-435 cells NUP1SJk3T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M{fnNFQ5KGh? MXvHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDNSGEuVUJvNEO1JINmdGy|IHHmeIVzKDR6IHjyd{BjgSCVUlKgZZN{[XluIFfJOVA:OC5yMEGg{txO Mlv6NlI6QDJzMkK=
OVCAR3 M4S5[Wdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MX60PEBp M2TPbGdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG9XS0GUMzDj[YxteyCjZoTldkA1QCCqcoOgZpkhW1KEIHHzd4F6NCCJSUWwQVAvODBzIN88US=> NVmzZWJTOjJ7OEKxNlI>
NCI/ADR-RES cells MkHGS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NFK1[|Q1QCCq MkjmS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gUmNKN0GGUj3SSXMh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IGPSRkBie3OjeTygS2k2OD1yLkCwNUDPxE1? MoK0NlI6QDJzMkK=
PC3 cells M1vn[Gdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NV;sdnZxPDhiaB?= Ml\rS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gVGM{KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDTVmIh[XO|YYmsJGdKPTB;MD6wNFEh|ryP M{D0fVIzQTh{MUKy
DU145 cells MnPqS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NVHtcGtOPDhiaB?= NX74Tm5yT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hTFVzNEWgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KFOUQjDhd5NigSxiR1m1NF0xNjByMTFOwG0> NFS1PIQzOjl6MkGyNi=>
MDA-MB-231 cells Mo[0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MWS0PEBp MoDkS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gUWRCNU2ELUKzNUBk\WyuczDh[pRmeiB2ODDodpMh[nliU2LCJIF{e2G7LDDHTVUxRTBwMECxJO69VQ>? NGrI[4szOjl6MkGyNi=>
CEM cells NGOzXJhEgXSxdH;4bYNqfHliYYPzZZk> NWPPdWZtPzJiaB?= MnTxR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gR2VOKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MD6wNFEh|ryP NInNWG0zOjZ5NkK0Oy=>
HCT116 cells MlTLR5l1d3SxeHnjbZR6KGG|c3H5 MWm3NkBp MUDDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME2wMlAxOSEQvF2= M2T2d|IzPjd4MkS3
MDA-MB-435 cells NVnYTZJoS3m2b4TvfIlkcXS7IHHzd4F6 NEXoRWQ4OiCq MYDDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvNEO1JINmdGy|IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:OC5yMEGg{txO MnvDNlI3PzZ{NEe=
HaCaT cells M3jlcnBzd2yrZnXyZZRqd25iYYPzZZk> MWrBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEijQ3HUJINmdGy|IHHzd4V{e2WmIHHzJINmdGxidnnhZoltcXS7IHL5JG1VXCCjc4PhfUwhUUN3ME2wMlAxOSEQvF2= MoK0NlMxPjN2MEG=
HL60 cells NVm1RXZ2WHKxbHnm[ZJifGmxbjDhd5NigQ>? MlLzO|IhcA>? NHvZT3dCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjMOlAh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1yLkCwNUDPxE1? M2roXVI{OTF5MUex
HL60 cells NIPqbZpRem:uaX\ldoF1cW:wIHHzd4F6 NH[5cno4OiCq M4rnVmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFy2NEBk\WyuczDh[pRmeiB5MjDodpMh[nliKEOtLFQtPS2maX3leIh6dHSqaXH6c4wuOi27bDmtNkw2NWSrcHjlcpltfGW2cnH6c4xqfW1iYoLvcYll\SC2ZYP0MEBKSzVyPUCuNFAyKM7:TR?= MYeyOVc5PTZyNR?=
HT-29 M1u3Vmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NHPPTJlIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBJXC1{OTDj[YxteyCkeTDNWHQh[XO|YYmsJGlEPTB;MD6wNFEh|ryP M{HNUlI2Pjh7MUGx
HL60 cells NXj3cZVUWHKxbHnm[ZJifGmxbjDhd5NigQ>? NW\mNoRvPzJiaB?= MlWyRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKTE[wJINmdGy|IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:OC5yMEGg{txO MYKyNFQzODR|OR?=
Hs578T cells NGXVdXlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4HFd|Q5KGh? MVPHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDId|U4QFRiY3XscJMh[W[2ZYKgOFghcHK|IHL5JHNTSiCjc4PhfUwhT0l3ME2wMlAxOSEQvF2= NVTEUHVkOjJ7OEKxNlI>
HL60 cells Mk\qR5l1d3SxeHnjbZR6KGG|c3H5 MoXpO|IhcA>? MkDzR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTGw3OCClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUCuNFAyKM7:TR?= MV:yN|Q1PTR7Nh?=
SKOV3 cells M4P2TWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MXTHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDTT29XOyClZXzsd{BjgSCPVGSgZZN{[XluIFnDOVA:OC5yMEGg{txO MVOyOVY5QTFzMR?=
MDA-MB-468 cells MnvER5l1d3SxeHnjbZR6KGG|c3H5 M{jmOlQh\GG7cx?= NHfHfnhEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOTEFvTVKtOFY5KGOnbHzzJIF{e2W|c3XkJIF{KGOnbHygeoli[mmuaYT5JIFnfGW{IESg[IF6eyCkeTDNWHMh[XO|YYmsJGlEPTB;MD6wNFEyKM7:TR?= NYLpOVJCOjR{MUC1NFM>
MCF7 cells NETSUG1Rem:uaX\ldoF1cW:wIHHzd4F6 Mn3mO|IhcA>? MkTPRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgbY4hcHWvYX6gUWNHPyClZXzsd{Bie3Onc4Pl[EBieyClZXzsJJZq[WKrbHn0fUBi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUCuNFAyOTFizszN MkDtNlI{Ojl3NkG=
H460 M{\5TGN6fG:2b4jpZ4l1gSCjc4PhfS=> MlrJR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTFQ3OCClZXzsd{BjgSC|dXzmc5Jpd2SjbXnu[UBDKHSnc4SsJGlEPTB;MD6wNFEzKM7:TR?= NHf6cXEyQDd6M{KwOy=>
H460 Ml;pVJJwdGmoZYLheIlwdiCjc4PhfS=> MUPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEh2NkCgZ4VtdHNuIFnDOVA:OC5yMEGyOEDPxE1? NUnPeVVMOTZ5MkK2N|M>
NCI-H460 cells NUfzO3dxS3m2b4TvfIlkcXS7IHHzd4F6 NILCR|A4OiCq NYXxdZVyS3m2b4TvfIlkKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gUmNKNUh2NkCgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KHO3bH\vdohw\GGvaX7lJGIhfGW|dDygTWM2OD1yLkCwNVMh|ryP NXy3Z4h[OTh|OU[4OVc>
OVCAR8 cells NEDWWopIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NF\IR5g6PiCq NVzvUIRYT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hV1[FQWK4JINmdGy|IH;2[ZJmgHC{ZYPzbY5oKFBvZ3z5Z49xem:2ZXnuJIFnfGW{IEm2JIhzeyxiSVO1NF0xNjByMUOg{txO NH3wbGozOjB2NEG2OC=>
NCI/ADR-RES cells NXf6UWJDS3m2b4TvfIlkcXS7IHHzd4F6 NWnHSmJsS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVkOLL1HEVk1TTVNiY3XscJMh[XO|ZYPz[YQh[XNiZ4Lve5RpKGmwaHnibZRqd25iYomgeJJ6eGGwIHLseYUh\XilbIXzbY9vKGG|c3H5MEBKSzVyPUCuNFAyOyEQvF2= M1\VUlI{OjF2NEWy
OVCAR8 cells MX3DfZRwfG:6aXPpeJkh[XO|YYm= MmrqPVYhcA>? M33CXWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG9XS0GUODDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB7NjDodpMh[nliR3nlcZNiKHO2YXnubY5oNWKjc3XkJIxq\2i2IH3pZ5Jwe2OxcImsJGlEPTB;MD6wNFE{KM7:TR?= NF3iRmszPTB{NUm5NS=>
NCI/ADR-RES cells MnX4R5l1d3SxeHnjbZR6KGG|c3H5 NFG3e4M6PiCq NX;aXYZsS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVkOLL1HEVk1TTVNiY3XscJMh[XO|ZYPz[YQh[XNiZ4Lve5RpKGmwaHnibZRqd25iYX\0[ZIhQTZiaILzJIJ6KEerZX3zZUB{fGGrbnnu[{1j[XOnZDDsbYdpfCCvaXPyc5Nkd3C7LDDJR|UxRTBwMECxN{DPxE1? NHfBbI0zPTB{NUm5NS=>
OVCAR8 cells NHm2bGdEgXSxdH;4bYNqfHliYYPzZZk> NV\pOWxDS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hV1[FQWK4JINmdGy|IHHzd4V{e2WmIHHzJIdzd3e2aDDpcohq[mm2aX;uJIJ6KHS{eYDhckBjdHWnIHX4Z4x2e2mxbjDhd5NigSxiSVO1NF0xNjByMUOg{txO NFfXZXIzOzJzNES1Ni=>
HuTu 80 cells M3PkPXBzd2yrZnXyZZRqd25iYYPzZZk> MWe3NkBp NHzwZYxCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBqdiCqdX3hckBJfVS3IEiwJINmdGy|IHHzd4V{e2WmIHHzJINmdGxidnnhZoltcXS7IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:OC5yMEGzO{DPxE1? MWqyNlMzQTV4MR?=
K562 cells MoXkR5l1d3SxeHnjbZR6KGG|c3H5 NX70TFJ[S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUzV4MjDj[YxteyxiSVO1NF0xNjByMUSg{txO MlfPNVk5Ozd3OUS=
NCI/ADR (MDR) cells NUDlTFk2TnWwY4Tpc44h[XO|YYm= MWnD[YxtKGO7Y3zlJIFzemW|dDDpckBPS0lxQVTSJEhOTFJrIHPlcIx{KGK7IHHjZ5VufWyjdHnvckBifCCJMj;NJJBp[XOnLDDJR|UxRTBwMECxOUDPxE1? MmHQNVY{PzdzOEe=
HUVEC NX;nS4NGWHKxbHnm[ZJifGmxbjDhd5NigQ>? M3fjc2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSGXWSWMtKEmFNUC9NE4xODF3IN88US=> NXfVSGp3OTZ5MkK2N|M>
KB cell M1fhZnBzd2yrZnXyZZRqd25iYYPzZZk> M3v3bWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iS1KgZ4VtdCCuaX7lJIJ6KG2ndHj5cIVv\SCkbIXlJIR6\SCjc4PhfUwhUUN3ME2wMlAxOTVizszN NE[0UGIyPzB|NEG0Oy=>
KB-VIN10 cell M1:1enBzd2yrZnXyZZRqd25iYYPzZZk> MmLORY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCNQj3WTW4yOCClZXzsJIxqdmViYomgcYV1cHmuZX7lJIJtfWViZInlJIF{e2G7LDDJR|UxRTBwMECxOUDPxE1? MYCxO|A{PDF2Nx?=
Human SH-SY5Y neuroblastoma cells MYLGeY5kfGmxbjDhd5NigQ>? M4raXmlvcGmkaYTvdpkh[2:wY3XueJJifGmxbjDh[4FqdnO2IFj1cYFvKFOKLWPZOXkhdmW3cn;icIF{fG:vYTDj[YxteyxiSVO1NF0xNjByMUWg{txO NFXqN3AyPTl4M{eyNi=>
SW620 cells NVHyfFlSWHKxbHnm[ZJifGmxbjDhd5NigQ>? MXy3NkBp MVnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDpckBpfW2jbjDTW|YzOCClZXzsd{Bie3Onc4Pl[EBieyClZXzsJJZq[WKrbHn0fUBi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUCuNFAyPTJizszN M2HQR|IzOzJ7NU[x
Molt4/C8 cells M4nHb3Bzd2yrZnXyZZRqd25iYYPzZZk> NX\3R5V5SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNc4x1PC:FODDj[YxteyxiSVO1NF0xNjByMU[g{txO M1\hVFE4ODN2MUWw
ACHN cell NWLCbmV7WHKxbHnm[ZJifGmxbjDhd5NigQ>? M3rlZWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4Sg[JJ2\yC{ZYPpd5RidnRiQVPIUkBk\WyuIHzpcoUh\XiycnXzd4lv\yCPRGKxJIJ6KEGuYX3hdkBDdHWnIHHzd4F6NCCLQ{WwQVAvODBzNjFOwG0> MWKxO|I5PjN7Mx?=
Molt4/C8 cells NX3sTo0{WHKxbHnm[ZJifGmxbjDhd5NigQ>? Mn7UN{Bl[Xm| MorMRY51cXC{b3zp[oVz[XSrdnWg[YZn\WO2IHHnZYlve3RiaIXtZY4hVW:udESvR|gh[2WubIOgZYZ1\XJiMzDkZZl{NCCLQ{WwQVAvODBzNjFOwG0> MUmxO|QyQTZyNx?=

... Click to View More Cell Line Experimental Data

In vivo In NT2 and MDA-MB-231 mammary tumor model, administration of Combretastatin A4 (100 mg/kg, i.p.) induces a significant decrease in lipids R1 and a reduction in tumor pO2 measured by electron paramagnetic resonance (EPR) oximetry.[2] Combretastatin A4 (100 mg/kg, i.p.) significant decreases the Ktrans in male NMRI mice.[3]

Protocol

Kinase Assay:[1]
- Collapse

Competitive binding assay using LC-MS/MS:

Colchicine (1.2 μ M) is incubated with tubulin (1.3 mg/mL) in the incubation buffer (80 mM PIPES, 2.0 mM MgCl2, 0.5 mM EGTA, pH 6.9) at 37℃ for 1 h. Varying concentrations (0.1 − 125 μ M) of Combretastatin A4 are used to compete with colchicine originally bound to tubulin. After incubation, the filtrate is obtained. The ability of the analogue to inhibit the binding of colchicine is expressed as a percentage of control binding in the absence of any competitor.
Cell Research:[1]
- Collapse
  • Cell lines: MDA-MB-231, A549, and Hela cells
  • Concentrations: ~3.8 nM
  • Incubation Time: 72 h
  • Method: MDA-MB-231, A549, and HeLa cells are grown in DMEM medium (115 units/mL of penicillin G, 115 μg/mL of streptomycin, and 10% fetal bovine serum). Cells are seeded in 96-well plates (5000 cells/well) containing 50 μL of growth medium for 24 h. After medium removal, 100 μL of fresh medium containing individual analogue compounds at different concentrations is added to each well and incubated at 37 ℃ for 72 h. After 24 h of culture, the cells are supplemented with 50 μL of analogue compounds dissolved in DMSO (less than 0.25% in each preparation). After 72 h of incubation, 20 μL of resazurin is added for 2 h before recording fluorescence at 560 nm (excitation) and 590 nm (emission) using a Victor microtiter plate fluorimeter. The IC50 is defined as the compound concentration required to inhibit cell proliferation by 50% in comparison with cells treated with the maximum amount of DMSO (0.25%) and considered as 100% viability.
    (Only for Reference)
Animal Research:[2]
- Collapse
  • Animal Models: FVB/N or nude NMRI female mice bearing NT2 and MDA-MB-231 tumors
  • Formulation: DMSO
  • Dosages: 100 mg/kg
  • Administration: i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 63 mg/mL (199.14 mM)
Ethanol 34 mg/mL warmed (107.47 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+50% PEG 300+ddH2O
For best results, use promptly after mixing.
30mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 316.35
Formula

C18H20O5

CAS No. 117048-59-6
Storage powder
in solvent
Synonyms N/A
Smiles COC1=C(O)C=C(\C=C/C2=CC(=C(OC)C(=C2)OC)OC)C=C1

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How to make solution for in vivo IP injection?

  • Answer:

    We've tested some vehicles for S7783 Combretastatin A4, and found it can be dissolved in 5% DMSO+50% PEG 300+ddH2O at 30mg/ml clearly. When prepare the solution, please dissolve the compound in DMSO clearly first. The add PEG, after they mixed well, then dilute with water.

Microtubule Associated Signaling Pathway Map

Related Microtubule Associated Products

Tags: buy Combretastatin A4 | Combretastatin A4 supplier | purchase Combretastatin A4 | Combretastatin A4 cost | Combretastatin A4 manufacturer | order Combretastatin A4 | Combretastatin A4 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID